Antithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization
Charles E. Mahan(Presbyterian Healthcare Services), Winslow Klaskala(Johnson & Johnson (United States)), Roger M. Mills(Janssen (Belgium)), An-Chen Fu(Wilmington University), Maxine D. Fisher(Wilmington University), Judith J. Stephenson(Wilmington University), Larry E. Fields(Janssen (United States)), Alex C. Spyropoulos(Lenox Hill Hospital)
Cited by 15
Related Papers
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
|European Heart Journal|2014|3.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH
|Journal of Thrombosis and Haemostasis|2015|1.4k
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
|New England Journal of Medicine|2015|1.2k
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
|New England Journal of Medicine|2013|603